Company Overview and News


Add GILD
to your dashboard

Headline News

Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?

2017-11-16 seekingalpha
The approval of Yescarta proved that CAR-T (based on CD4 T cells) works. Atara uses a similar mechanism of action and targets the CAR-T (that leverages on CD8). (27-0)

How To Make Money With Gilead?

2017-11-16 seekingalpha
Growth of the Hepatitis franchises seem to be at the end of its robust cycle, but tapping into the vast China market may spark further growth. (51-0)

Astellas faces U.S. probe over patient assistance charity support

2017-11-15 reuters
BOSTON (Reuters) - Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers’ financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Astellas faces US probe over patient assistance charity support

2017-11-15 channelnewsasia
Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Trade of the Day: Gilead Sciences, Inc. (GILD) | InvestorPlace

2017-11-15 investorplace
To receive further updates on this Gilead Sciences, Inc. (NASDAQ:GILD) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.  (20-0)

7 Vanguard ETFs to Build a Total Portfolio

2017-11-14 investorplace
When you’re putting together a portfolio — whether you’re starting one tomorrow, or you’re looking to tinker with what you’ve got — there are a few basics that most investors aim for: U.S. stocks. International holdings. Fixed income. (57-0)

7 Life Science Stocks to Buy Today | InvestorPlace

2017-11-14 investorplace
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like? (236-1)

Why Argus Is Taking a Step Back on Gilead Sciences

2017-11-13 247wallst
Gilead Sciences Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have hoped that the shares will pull out of their holding pattern with some M&A, but this boost only proved temporary. As a result more analysts are taking a more sideline approach to this stock. (20-0)

Biotech ETFs: What Lies Ahead?

2017-11-13 zacks
So far, it’s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date. This is in sharp contrast to last year’s performance when the Index was down 19.1% with several factors including the drug pricing controversy weighing on the sector. (177-0)

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and Many More

2017-11-13 247wallst
Stocks were indicated to open lower on Monday, with all major U.S. equity indexes down about 0.3% on average. What investors still need to consider is that the stock indexes have bumped up against all-time highs, and the trend that has dominated is that investors have bought every major sell-off for more than five years now. Investors are also looking for new investing and trading ideas to generate gains and income ahead. (385-1)

Tesaro: Multiple Drivers Ahead, Not Pulling The Trigger

2017-11-13 seekingalpha
The latter is very promising even as the short-term revenue guidance is soft, as a European launch and approval for other indications could drive further growth. (77-0)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-8)

Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-VIgD

2017-11-12 seekingalpha
Kite Pharma licensed TIP-vIgD from Alpine Immune Science for CAR-TCR innovation. Gilead recently acquired Kite for the powerful CAR-TCR platform. (20-0)

BioLife Solutions' (BLFS) CEO Mike Rice on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the Third Quarter 2017 BioLife Solutions Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (40-0)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

CUSIP: 375558953